Drug Trial Radar · NCT07220109
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
750
Actual
Start
Oct 29, 2025
Primary completion
Jul 20, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the immune response generated in older adults 60 YOA and above from the 219815 (RSV OA=ADJ-021; NCT06551181) study following a single dose of the RSVPreF3 OA vaccine. In addition, the safety and reactogenicity of the vaccine will also be assessed.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA vaccineBiological
1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
PlaceboBiological
1 dose of saline solution administered intramuscularly in the deltoid region of the non-dominant arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RSV-A neutralizing titers expressed as group Geometric Mean Titers (GMTs)Time frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
- RSV-A neutralizing titers expressed as group Seroresponse rate (SRR)Time frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
- RSV-B neutralizing titers expressed as group GMTsTime frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
- RSV-B neutralizing titers expressed as group SRRTime frame: At Day 31 (i.e., 1 month after RSVPreF3 OA investigational vaccine administration)
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Jiujiang, China
GSK Investigational Site
Kunming, China
GSK Investigational Site
Nanning, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Zhuhai, China
GSK Investigational Site
Beijing, Beijing Municipality, China
GSK Investigational Site
Xiangtan, Hunan, China
GSK Investigational Site
Nanjing, Jiangsu, China
GSK Investigational Site
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.